Stock Fundamentals

Company Information

Company Name
Ocular Therapeutix Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US67576A1007
CIK: 0001393434
CUSIP: 67576A100
Currency: USD
Full Time Employees: 325
Phone: 781 357 4000
Fiscal Year End: December
IPO Date: Jul 25, 2014
Description:

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Address:

14 Crosby Drive, Bedford, MA, United States, 01730

Directors & Officers

Name Title Year Born
Dr. Pravin U. Dugel M.D. Executive Chairman, President & CEO 1964
Mr. Steve Meyers Chief Commercial Officer NA
Mr. Sanjay Nayak MBBS, Ph.D. Chief Strategy Officer 1970
Dr. Nadia K. Waheed M.D., M.P.H. Chief Medical Officer 1977
Dr. Peter K. Jarrett Ph.D. Chief Technical Officer 1957
Dr. Jeffrey S. Heier M.D. Chief Scientific Officer 1961
Mr. William S. Slattery Jr. Vice President of Investor Relations NA
Mr. Todd D.C. Anderman J.D. Chief Legal Officer & Corporate Secretary 1982
Mr. William H. Ransone II Vice President of Global Sales & Marketing NA
Dr. Peter K. Kaiser M.D. Chief Development Officer 1967

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 23, 2026 Peter Kaiser N/A Sale 2.81K $8.28 $23.27K
Feb 23, 2026 Pravin Dugel N/A Sale 20.06K $8.28 $166.06K
Feb 23, 2026 Sanjay Nayak N/A Sale 1.76K $8.28 $14.56K
Feb 23, 2026 Jeffrey S Heier N/A Sale 3.06K $8.28 $25.31K
Feb 20, 2026 Nadia Waheed N/A Sale 3.51K $7.74 $27.17K
Feb 20, 2026 Richard L Md Lindstrom N/A Purchase 60.23K $7.66 $461.35K
Feb 12, 2026 Donald Notman N/A Sale 11.45K $9.04 $103.47K
Feb 12, 2026 Nadia Waheed N/A Sale 7.86K $9.04 $71.08K
Feb 12, 2026 Pravin Dugel N/A Sale 124.88K $9.04 $1.13M
Feb 12, 2026 Sanjay Nayak N/A Sale 10.35K $9.04 $93.55K
Feb 04, 2026 Donald Notman N/A Sale 6.04K $8.54 $51.54K
Feb 02, 2026 Donald Notman N/A Sale 5.46K $9.14 $49.86K
Oct 08, 2025 Todd Anderman N/A Sale 11.13K $12.34 $137.37K
Oct 02, 2025 Jeffrey S Heier N/A Sale 10.50K $11.04 $115.94K
Oct 02, 2025 Peter Kaiser N/A Sale 9.65K $11.03 $106.47K
Sep 02, 2025 Donald Notman N/A Sale 1.07K $12.43 $13.25K
Aug 25, 2025 Jeffrey S Heier N/A Sale 3.06K $12.04 $36.88K
Aug 25, 2025 Peter Kaiser N/A Sale 3.01K $12.04 $36.25K
Aug 25, 2025 Pravin Dugel N/A Sale 21.49K $12.04 $258.79K
Aug 25, 2025 Sanjay Nayak N/A Sale 1.89K $12.04 $22.70K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 32.65M Mar 31, 2026 14.91% $0.01 2.73%
Deep Track Capital, LP 19.69M Mar 31, 2026 8.99% $2.72 143.93%
BlackRock Inc 16.13M Mar 31, 2026 7.37% $0.00 3.40%
venBio Select Advisor LLC 12.32M Mar 31, 2026 5.62% $1.03 14.26%
SUMMER ROAD LLC 11.88M Mar 31, 2026 5.43% $70.84 6.94%
Vanguard Group Inc 11.58M Dec 31, 2025 5.29% $0.00 26.32%
VR Adviser, LLC 10.35M Mar 31, 2026 4.73% $3.27 41.44%
Vanguard Capital Management, LLC 8.72M Mar 31, 2026 3.98% $0.00 0.00%
T. Rowe Price Associates, Inc. 5.90M Mar 31, 2026 2.69% $0.01 3,338.09%
Point72 Asset Management, L.P. 5.53M Mar 31, 2026 2.53% $0.06 444.65%
State Street Corp 4.71M Mar 31, 2026 2.15% $0.00 12.20%
Geode Capital Management, LLC 4.53M Mar 31, 2026 2.07% $0.00 3.96%
AllianceBernstein L.P. 4.13M Mar 31, 2026 1.89% $0.02 -4.89%
Logos Global Management LP 3.85M Mar 31, 2026 1.76% $1.63 10.00%
Octagon Capital Advisors LP 3.17M Mar 31, 2026 1.45% $2.97 20.70%
Balyasny Asset Management LLC 2.69M Mar 31, 2026 1.23% $0.03 252.64%
COMMODORE CAPITAL LP 2.58M Mar 31, 2026 1.18% $1.26 0.00%
Deltec Asset Management LLC 2.34M Mar 31, 2026 1.07% $3.64 -5.92%
Two Sigma Investments LLC 1.83M Mar 31, 2026 0.84% $0.01 380.72%
Woodline Partners LP 1.67M Mar 31, 2026 0.76% $0.05 0.09%

Shares Statistics

Shares Outstanding: 218.96M
Shares Float: 184.40M
% Insiders: 89.70%
% Institutions: 9,566.30%
Short % Float: 13.53%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 13.04M 5.95% ▲ 0.07% Apr 30, 2026
2 Fidelity Growth Company Fund 9.65M 4.41% ▲ 0.00% Apr 30, 2026
3 Vanguard Total Stock Mkt Idx Inv 6.58M 3.00% ▲ 0.35% Apr 30, 2026
4 iShares Russell 2000 ETF 4.49M 2.05% ▲ 0.93% May 29, 2026
5 Fidelity Growth Company K6 2.68M 1.22% ▼ 0.32% Apr 30, 2026
6 Fidelity Series Growth Company 2.59M 1.19% ▲ 0.00% Apr 30, 2026
7 Vanguard Institutional Extnd Mkt Idx Tr 1.97M 0.90% ▲ 0.79% Apr 30, 2026
8 Fidelity Small Cap Index 1.84M 0.84% ▲ 1.21% Mar 31, 2026
9 T. Rowe Price New Horizons 1.79M 0.82% ▲ 21.30% Apr 30, 2026
10 iShares Russell 2000 Growth ETF 1.53M 0.70% ▼ 0.65% May 29, 2026

Valuation Metrics

Enterprise Value: $1.37B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $1.96B
EBITDA: $-294.82M
PEG Ratio: $0.00
Book Value: $2.66
Earnings/Share: $-1.44
Profit Margin: 0.00%
Operating Margin: -865.46%
ROA (TTM): -32.88%
ROE (TTM): -68.55%
Revenue (TTM): $52.04M
Revenue/Share (TTM): $0.26
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.80%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 15.39x 0.11x 0.19x -22.82x -0.30x
2024-12-31 10.66x 0.22x 0.31x -12.65x -0.40x
2023-12-31 6.66x 0.84x 0.64x -7.27x -1.15x
2022-12-31 4.13x 1.57x 0.76x -11.20x -0.90x
2021-12-31 7.26x 0.60x 0.57x -11.70x 20.90x
2020-12-31 9.23x 0.67x 0.71x -9.29x -0.35x
2019-12-31 5.00x -13.89x 1.05x -14.06x -0.65x
2018-12-31 6.14x 0.69x 0.51x -34.00x -0.44x
2017-12-31 3.23x 0.69x 0.53x -32.73x -0.30x
2016-12-31 8.42x 0.30x 0.31x -25.79x -0.37x
2015-12-31 19.89x 0.34x 0.19x -22.16x -0.82x
2014-12-31 12.97x 0.25x 0.25x -24.21x -0.55x
2013-12-31 5.39x -0.04x 4.11x -29.26x -0.20x
2012-12-31 6.98x -0.09x 2.84x -36.26x -0.31x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about OCUL.US!